CBAY
Cymabay Therapeutics
CBAY
CBAY
Delisted
CBAY was delisted on the 21st of March, 2024.
131 hedge funds and large institutions have $458M invested in Cymabay Therapeutics in 2018 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 40 increasing their positions, 37 reducing their positions, and 27 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
131
Holders Change
-1
Holders Change %
-0.76%
% of All Funds
2.92%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.09%
New
27
Increased
40
Reduced
37
Closed
27
Calls
$250K
Puts
$454K
Net Calls
-$204K
Net Calls Change
-$301K
Top Buyers
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$11.2M |
| 2 |
BlackRock
New York
|
+$5.69M |
| 3 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$4.78M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$3.69M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.92M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$9M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$8.12M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.55M |
| 4 |
AG
Artal Group
Luxembourg
|
-$2.36M |
| 5 |
PA
Perceptive Advisors
New York
|
-$2.2M |
